about
Melatonin for Prevention of Metabolic Side Effects of OlanzapinePatient, Treatment, and Health Care Utilization Variables Associated with Adherence to Metabolic Monitoring Practices in Children and Adolescents Taking Second-Generation AntipsychoticsCross-Sectional Iloperidone IVGTTAssociation of Multiple Genetic Polymorphisms With Clozapine-Associated Metabolic Change in SchizophreniaSpecialized Clozapine Clinic for Bipolar and Schizoaffective DisorderNovel Candidate Genes for Treatment Response to Antipsychotics in SchizophreniaMonitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population
P921
Q63843286-CACE56E0-3F99-4E96-A335-279F7CF84795Q64332771-920CF4B1-9CD6-4779-AAEC-AEB37E9B2998Q64641351-58F67079-D447-44B9-8645-B96AAACCEC1AQ64718283-BD598569-E6A7-42EF-98F8-3E5830A5B532Q65378105-BF88E5E3-E292-4588-A9DF-6CBF228B80DAQ67134851-7A58D75A-D5FA-41C2-8680-C76A9A082974Q94982422-7730263F-8DE0-4FF0-A999-50466519B852
P921
description
specific effects of drugs and substances on metabolic pathways
@en
name
efectos secundarios metabólicos de fármacos y sustancias
@es
metabolic side effects of drugs and substances
@en
type
label
efectos secundarios metabólicos de fármacos y sustancias
@es
metabolic side effects of drugs and substances
@en
prefLabel
efectos secundarios metabólicos de fármacos y sustancias
@es
metabolic side effects of drugs and substances
@en
P486
P672
P486
P672
D27.505.389